The global HER2-Positive Breast Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
HER2, also known as human epidermal growth factor receptor 2, is an important prognostic factor for breast cancer.HER2 is also expressed on the surface of some normal cells in the body.Her2-positive breast cancer is characterized by strong invasion, more recurrence and metastasis, and short disease-free survival.
This report aims to provide a comprehensive presentation of the global market for HER2-Positive Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HER2-Positive Breast Cancer. This report contains market size and forecasts of HER2-Positive Breast Cancer in global, including the following market information:
- Global HER2-Positive Breast Cancer Market Revenue, 2018-2023, 2024-2032, ($ millions)
- Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Grifola Frondosa Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of HER2-Positive Breast Cancer include Pfizer (Pharmacia and Upjohn Company), Novartis, AstraZeneca Pharmaceuticals, Eli Lilly, Roche Group, Merck, Jiangsu HengRui Medicine, Odonate Therapeutics and Radius Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the HER2-Positive Breast Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global HER2-Positive Breast Cancer Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global HER2-Positive Breast Cancer Market Segment Percentages, by Type, 2022 (%)
- Grifola Frondosa
- Surgery
- Radiation and Chemotherapy
- Endocrine Therapy
- Molecular Targeted Therapy
Global HER2-Positive Breast Cancer Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global HER2-Positive Breast Cancer Market Segment Percentages, by Application, 2022 (%)
- Hospital
- Specialist Clinic
- Biotechnology and Pharmaceutical Companies
- Research and Academic Institutions
- Other
Global HER2-Positive Breast Cancer Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global HER2-Positive Breast Cancer Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies HER2-Positive Breast Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies HER2-Positive Breast Cancer revenues share in global market, 2022 (%)
key players include:
- Pfizer (Pharmacia and Upjohn Company)
- Novartis
- AstraZeneca Pharmaceuticals
- Eli Lilly
- Roche Group
- Merck
- Jiangsu HengRui Medicine
- Odonate Therapeutics
- Radius Pharmaceuticals
- Immunomedics
- Syndax Pharmaceuticals
- Bayer
- Eagle Pharmaceuticals
- Merrimack Pharmaceuticals
- GlaxoSmithKline
- Millennium Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of HER2-Positive Breast Cancer, market overview.
Chapter 2: Global HER2-Positive Breast Cancer market size in revenue.
Chapter 3: Detailed analysis of HER2-Positive Breast Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of HER2-Positive Breast Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
